Selank peptide is investigated as a CNS-active and immunomodulatory tool compound
across a range of preclinical neuropharmacology and neuroimmunology research domains.
Documented areas of scientific investigation include:

• GABAergic system modulation — anxiolytic mechanistic studies without classical BZD pharmacology
• Enkephalin metabolism — leucine-enkephalin aminopeptidase inhibition and opioid peptide tone research
• BDNF and neurotrophin expression in hippocampal and cortical rodent models
• HPA axis and stress response — corticosterone modulation under acute and chronic stress protocols
• Neuroimmunology — IL-6, TNF-α, and interferon expression in immune cell populations
• Serotonergic pathway modulation in anxiety and depression-related rodent paradigms
• Tuftsin receptor pharmacology — macrophage and NK cell activity in immunological models

Selank is not approved for therapeutic use in Western jurisdictions and is supplied
strictly for laboratory-based scientific investigation.

While Selank and Semax share the same C-terminal Pro-Gly-Pro stabilising extension and were
both developed at the same Russian research institution, they are structurally and mechanistically
distinct compounds derived from different parent sequences. Semax is an ACTH(4-7) analogue
whose research activity centres primarily on BDNF upregulation, neuroprotection in ischaemia
models, and dopaminergic system modulation. Selank is a tuftsin analogue whose primary
documented research profile centres on GABAergic anxiolytic activity, enkephalin system
modulation, and immunomodulatory effects inherited from the tuftsin core. Although both
compounds show some BDNF-upregulating activity in preclinical models, Selank is more
commonly used in research examining anxiolytic pharmacology and neuroimmune interactions,
while Semax is more typically employed in neuroprotective and cognitive neuroscience research.
They are pharmacologically complementary rather than interchangeable tool compounds.

Tuftsin (Thr-Lys-Pro-Arg) is an endogenous tetrapeptide naturally generated by cleavage
from the CH2 domain of the IgG heavy chain by the splenic enzyme tuftsin endocarboxypeptidase.
It exerts immunostimulatory activity through interaction with tuftsin receptors expressed
on monocytes, macrophages, neutrophils, and natural killer cells, enhancing phagocytic
activity, cytokine production, and anti-tumour immune responses. In Selank, the intact
tuftsin sequence forms residues 1–4 and is proposed to contribute the immunomodulatory
component of the compound’s research profile, while the added CNS-targeting activity is
attributed to a combination of the full seven-residue peptide’s receptor interactions and
the pharmacokinetic advantages conferred by the Pro-Gly-Pro extension. This dual
immunological-neurological mechanistic origin makes Selank a research tool of particular
interest in neuroimmunology and CNS-immune axis studies.

Once reconstituted in sterile water, PBS, or bacteriostatic water, Selank solutions
should be stored at 2–8 °C and used within 28 days. Selank does not contain
methionine or cysteine residues, meaning it does not carry the oxidation-sensitivity
that requires special handling precautions for some other neuropeptide tool compounds.
Standard peptide solution handling applies: refrigerate after reconstitution, protect
from light, avoid repeated freeze-thaw cycling of the reconstituted product, and
discard any solution showing visible turbidity or colour change, which may indicate
microbial contamination or advanced degradation. Lyophilised, unopened vials should
remain at −20 °C until the point of use.

A purity specification of ≥99% indicates that at least 99% of the total material,
by mass, is confirmed to be the intact Selank heptapeptide sequence, with the remaining
fraction comprising quantified impurities at or below 1% total — determined by
reverse-phase HPLC and confirmed by ESI-MS. For Selank research specifically, impurity
control is particularly important in GABAergic assay contexts, where even minor
contaminating peptide fragments could interact independently with GABA-A receptor
subunits or modify endogenous GABA-ergic tone, introducing confounding variables that
would complicate interpretation of Selank’s receptor-level effects. Similarly, for
enkephalin enzyme inhibition studies, truncated Selank sequences may exhibit differential
enzyme binding, potentially altering leucine-enkephalin half-life measurements.
High-purity material ensures that experimental results are attributable to the full
intact peptide rather than artefacts of synthesis impurity.

Yes. Baltic Peptides issues a batch-specific Certificate of Analysis for every
production lot of Selank research peptide. Each COA documents HPLC purity data
including impurity profiling, mass spectrometry identity confirmation of the full
TKPRPGP sequence, lot number, manufacturing and testing dates, and the analytical
method parameters applied by the independent testing laboratory. Researchers may
request the current batch COA via the Baltic Peptides support portal prior to or
following purchase. All historical lot documentation is archived and available
upon inquiry.

Selank is dispatched in lyophilised form, providing inherent thermal and chemical
stability advantages over liquid peptide preparations during transit. All Baltic
Peptides orders are packaged with temperature-protective materials appropriate for
lyophilised neuropeptide research compounds. Baltic Peptides dispatches from within
the EU, providing shorter transit times and reduced customs exposure for European
research institutions. Cold-chain insulated packaging is available upon request
for orders requiring additional temperature assurance. Each shipment includes
product labelling stating lot number, storage conditions, and research-use-only
classification. Expedited shipping options are available for time-sensitive
research requirements on request.